Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

PURPOSE: Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody, has demonstrated improved survival in previously treated patients with advanced non–small-cell lung cancer (NSCLC). CheckMate 012, a phase I, multicohort study, was conducted to explore the s...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Oncol
Главные авторы: Rizvi, Naiyer A., Hellmann, Matthew D., Brahmer, Julie R., Juergens, Rosalyn A., Borghaei, Hossein, Gettinger, Scott, Chow, Laura Q., Gerber, David E., Laurie, Scott A., Goldman, Jonathan W., Shepherd, Frances A., Chen, Allen C., Shen, Yun, Nathan, Faith E., Harbison, Christopher T., Antonia, Scott
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2016
Предметы:
ORIGINAL REPORTS
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569693/
https://ncbi.nlm.nih.gov/pubmed/27354481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.66.9861
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы